Navigation Links
Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
Date:2/5/2008

MADISON, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its Board of Directors has elected Timothy P. Cost, 48, to the position of Senior Vice President, Corporate Affairs effective immediately. Mr. Cost replaces Marily H. Rhudy, 59, who has announced her plans to retire.

Prior to joining Wyeth, Mr. Cost was Executive Vice President, Corporate Affairs at ARAMARK since 2003. During his 27-year career, he has served in senior executive roles for several leading companies. He formerly was Senior Vice President of Corporate Affairs for Pharmacia and, prior to that, Vice President of Investor Relations and Corporate Intelligence for Bristol-Myers Squibb Company. He also served as Senior Vice President, Communications and Strategy for Centocor, Inc. Mr. Cost began his career with Kodak, holding a number of management positions with the company, including Director of Strategic Planning, Worldwide Operations and Vice President, Investor Relations.

Mr. Cost earned his undergraduate degree from Jacksonville University in Florida and holds an M.B.A. in Finance and Economics from the William E. Simon Graduate School of Business at the University of Rochester.

"I am pleased to have a leader of Tim's caliber joining the senior management team," says Bernard Poussot, President and Chief Executive Officer, Wyeth. "His extensive and broad experience, especially in the biotechnology and pharmaceutical sectors, will help us as we continue to deliver innovative new products and navigate the changing business environment."

Ms. Rhudy joined Wyeth in 1993 as Assistant Vice President, Professional Relations for Wyeth's pharmaceuticals division and held positions of increasing responsibility while building Wyeth's public affairs function. She was promoted to Vice President, Corporate Public Affairs, Wyeth in 1997 and Senior Vice President, Corporate Public Affairs, Wyeth in 2004. Before joining Wyeth, she was appointed by the President to the White House Health Care Professionals Task Force on Health Care Reform in 1993.

"Marily has built an outstanding public affairs team that has forged strong external relationships to raise the level of awareness of Wyeth's contributions to health care," says Mr. Poussot. "In addition, her team has partnered across the Wyeth divisions to resolve complex business and product issues and to help the Company achieve its business goals. We thank Marily for her many contributions to our business."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
3. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
4. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
7. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
8. Wyeth Declares Preferred Stock Dividend
9. Wyeth Announces Election of New Principal Corporate Officer
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation ... infertility as a disease, bringing new hope for prospective parents who are challenged ... meeting to back the World Health Organization’s designation in hopes of changing the ...
(Date:6/22/2017)... Lawrence, MA (PRWEB) , ... June 22, 2017 , ... ... completed ILVO validation. The AMPH test was determined to be appropriate as a screening ... for visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. ...
(Date:6/20/2017)... ... June 20, 2017 , ... National ... well-versed leader with extensive assay development and biomarker expertise, as VP of Scientific ... Boston CRO specializing in bio-analytical assay development and sample testing services. The organization ...
(Date:6/19/2017)... ... June 19, 2017 , ... Tunnell Consulting has been solving the ... the biggest challenges faced by life sciences, biotech and pharmaceuticals companies today is in ... Kati Abraham , who is well known in the industry and brings significant high-level ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):